• Submit to IJMS Login Register
• MDPI
• Journals A-Z
• For Authors
• For Editors
• About
• Open Access Policy

• Abstract
• Full-Text PDF [182 KB]
• Full-Text XML
• Article Versions Notes

• Article Statistics
• PubMed/Medline
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Spratlin, J
• Mulder, K
• [+] on Google Scholar
• Spratlin, J
• Mulder, K
• [+] on PubMed
• Spratlin, J
• Mulder, K

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Int. J. Mol. Sci. 2011, 12(9), 5895-5907; doi:10.3390/ijms12095895

Review

Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma

Jennifer L. Spratlin*  and Karen E. Mulder*

Department of Oncology, Cross Cancer Institute, School of Cancer, Imaging and Engineering Sciences, Faculty of Medicine and Dentistry, University of Alberta, 11560 University Avenue, Edmonton, Alberta, T6G 1Z2, Canada

* Authors to whom correspondence should be addressed.

Received: 5 August 2011; in revised form: 30 August 2011 / Accepted: 8 September 2011 / Published: 14 September 2011

(This article belongs to the Special Issue Biomarkers 2011)

Download PDF Full-Text [182 KB, uploaded 14 September 2011 16:53 CEST]

Abstract: The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biomarkers to help direct therapy in this area, there is little action to move them into clinical practice. Herein, we review potential pancreatic cancer biomarkers and discuss the limitations in their implementation.

Keywords: pancreatic adenocarcinoma; hENT1; hCNT3; SPARC; cDK; biomarker; clinical trials; gemcitabine; oxaliplatin

Article Statistics

Cite This Article